No Makeup, No Problem

And then everything changed. Towards the end of my high school years, I started finding self-worth from myself instead of others. I started taking pride in my accomplishments instead of my appearance, and I put all of my energy into improving myself and my relationships with my family and friends. Little by little, I learned that my appearance wasn’t really important at all. Being a good person, a good friend, a good family member – that’s all that matters. It’s something that I’d always known inside, but it’s hard to listen to your intuition when you’re a teenager.



● Soolantra ® (ivermectin) Cream, 1% for the treatment of inflammatory lesions or bumps and pimples of rosacea
● Oracea ® (doxycycline, USP) 40mg* Capsules, for the treatment of only the bumps and pimples of rosacea
● Mirvaso ® (brimonidine) Gel, 0.33%** for the treatment of the persistent facial redness of rosacea
As always, be sure to consult your doctor before using any new product. You can find important safety information about these products below.
Important Safety Information – Soolantra ® Cream
Indication: SOOLANTRA® (ivermectin) Cream, 1% is indicated for the treatment of inflammatory lesions of rosacea. Not for oral, ophthalmic or intravaginal use. Adverse Events: In clinical trials with SOOLANTRA Cream, the most common adverse reactions (incidence ≤1 %) included skin burning sensation and skin irritation.
Full Prescribing Information
Important Safety Information – Oracea ® Capsules
Indication: ORACEA® (doxycycline, USP) 40 mg* Capsules are indicated for the treatment of only inflammatory lesions (papules and pustules) of rosacea in adult patients. ORACEA Capsules do not lessen the facial redness caused by rosacea. Adverse Events: In controlled clinical studies, the most commonly reported adverse events (>2%) in patients treated with ORACEA Capsules were nasopharyngitis, sinusitis, diarrhea, hypertension and aspartate aminotransferase increase. Warnings/Precautions: ORACEA Capsules should not be used to treat or prevent infections. ORACEA Capsules should not be taken by patients who have a known hypersensitivity to doxycycline or other tetracyclines. ORACEA Capsules should not be taken during pregnancy, by nursing mothers, or during tooth development (upto the age of 8 years). Although photosensitivity was not observed in clinical trials, ORACEA Capsules patients should minimize or avoid exposure to natural or artificial sunlight. The efficacy of ORACEA Capsules treatment beyond 16 weeks and safety beyond 9 months have not been established.
*30 mg immediate release & 10 mg delayed release beads
Full Prescribing Information
Important Safety Information – Mirvaso ® Gel
Indication: MIRVASO® (brimonidine) topical gel, 0.33%** is an alpha adrenergic agonist indicated for the topical treatment of persistent (nontransient) facial erythema of rosacea in adults 18 years of age or older. Adverse Events: In clinical trials, the most common adverse reactions (≥1%) included erythema,flushing, skin burning sensation and contact dermatitis. Warnings/Precautions: MIRVASO Gel should be used with caution in patients with depression, cerebral or coronary insufficiency, Raynaud's phenomenon, orthostatic hypotension, thromboangiitis obliterans, scleroderma, or Sjögren’s syndrome.Alpha-2 adrenergic agents can lower blood pressure. MIRVASO Gel should be used with caution in patients with severe or unstable or uncontrolled cardiovascular disease. Serious adverse reactions following accidental ingestion of MIRVASO Gel by children have been reported. Keep MIRVASO Gel out of reach of children. Not for oral, ophthalmic, or intravaginal use.
**Each gram of gel contains 5 mg of brimonidine tartrate, equivalent to 3.3 mg of brimonidine free base
Full Prescribing Information
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit WWW.FDA.GOV/MEDWATCH or call 1-800- FDA-1088.
All trademarks are the property of their respective owner.